DNA Script
Founded in 2014 in Paris, DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science. The company is pioneering an alternative to traditional DNA synthesis called enzymatic DNA synthesis (EDS), making this technology accessible to labs with the world’s first benchtop enzymatic synthesis instrument, SYNTAX (TM). By putting DNA synthesis back in the lab, DNA Script is transforming life science research through innovative technology that gives researchers unprecedented autonomy.
Sector
Industrial Biotech
Strategy
Industrial Biotech
Website
www.dnascript.com
Related News
Sofinnova Partners congratulates portfolio company DNA Script for the success of its €142M ($165M) Oversubscribed Series C Fundraise
DNA Script Expands Series B to $89M
Sofinnova Partners’ DNA Script Raises $38.5 Million in Series B Financing
DNA Script Announces World's First Enzymatic Synthesis of a High-Purity 200-Nucleotide Strand of DNA
DNA Script Announces World’s First Enzymatic Synthesis of a High-Purity 150-Nucleotide Strand of DNA
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.